(Q30992939)

English

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

author name string

Simon B Zeichner

1

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Stuart Herna

2

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Aruna Mani

3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Tadeu Ambros

4

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Alberto J Montero

5

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Reshma L Mahtani

6

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Eugene R Ahn

7

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Charles L Vogel

8

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

language of work or name

0 references

publication date

10 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

153

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

617-624

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

https://scigraph.springernature.com/pub.10.1007/s10549-015-3564-3

0 references

Survival differences among women with de novo stage IV and relapsed breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Breast cancer with synchronous metastases: trends in survival during a 14-year period

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Primary and secondary distant metastatic breast cancer: two sides of the same coin.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

FEC (5-fluorouracil, epidoxorubicin and cyclophosphamide) versus EM (epidoxorubicin and mitomycin-C) with or without lonidamine as first-line treatment for advanced breast cancer. A multicentric randomised study. Final results.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Surgery of the primary tumor does not improve survival in stage IV breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Racial differences in outcomes for patients with metastatic breast cancer by disease subtype

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-015-3564-3

21 January 2018

Identifiers

10.1007/S10549-015-3564-3

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30992939&oldid=1672276537"